Great Point Partners LLC Zymeworks Inc. Transaction History

Great Point Partners LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$29.83 - $56.81 $23.9 Million - $45.4 Million	-799,722 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$39.12 - $54.99 $30.1 Million - $42.2 Million	-768,178 Reduced 48.99%	799,722 $37.8 Million
Q3 2020 Nov 16, 2020	SELL	$29.21 - $46.58 $29.4 Million - $46.9 Million	-1,006,788 Reduced 39.1%	1,567,900 $73 Million
Q2 2020 Aug 14, 2020	BUY	$33.67 - $40.0 $8.42 Million - $10 Million	250,000 Added 10.75%	2,574,688 $92.9 Million
Q1 2020 May 15, 2020	BUY	$24.28 - $49.8 $2.45 Million - $5.02 Million	100,899 Added 4.54%	2,324,688 $82.5 Million
Q4 2019 Feb 14, 2020	SELL	$24.84 - $45.46 $6.04 Million - $11 Million	-242,955 Reduced 9.85%	2,223,789 $101 Million
Q3 2019 Nov 15, 2019	BUY	$22.78 - $29.08 $32 Million - $40.8 Million	1,402,703 Added 131.83%	2,466,744 $61.2 Million
Q2 2019 Aug 14, 2019	BUY	$15.0 - $22.49 $15.7 Million - $23.6 Million	1,049,431 Added 7182.96%	1,064,041 $0
Q1 2019 May 14, 2019	BUY	$14.02 - $16.74 $204,832 - $244,571	14,610 New	14,610 $236,000
Q4 2018 Feb 15, 2019	SELL	$10.95 - $15.44 $2.65 Million - $3.74 Million	-241,970 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$12.21 - $16.61 $2.95 Million - $4.02 Million	241,970 New	241,970 $3.8 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $906M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.